Neuromyelitis Optics Therapy Market Size Share Trends Forecast 2027

1. NEUROMYELITIS OPTICS THERAPY MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

2. REPORT DESCRIPTION Neuromyelitis Optics Therapy Market - Overview Global Neuromyelitis Optica Therapy Market Drivers The global Neuromyelitis Optica Therapy Market is expected to witness significant growth over the forecast period, owing to increasing collaborations to launch new drugs for the treatment of neuromyelitis optica spectrum disorder. For instance, in May 2019, in China, Viela Bio, Inc. entered into strategic collaboration with Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”) to develop as well as commercialize inebilizumab drug for the treatment of autoimmune disorder such as neuromyelitis optica spectrum disorder. From the same source, in May 2019, Viela Bio had presented positive result from the pivotal study of inebilizumab in patient. Moreover, currently inebilizumab drug is not approved by the U.S Food and Drug Administartion (FDA) for sale in China and U.S. Neuromyelitis optica is an autoimmune disorder, in which white blood cells and antibodies attack optic nerve as well as spinal cord. Furthermore, damage of the optics nerves results in pain and loss of vision, while damage of spinal cord results in paralysis of legs or arms, loss of sensation in legs and arms, and problem in the function of bladder & bowel. Moreover, there is no cure for neuromyelitis optica disorder, but there are therapies to treat acute attack of relapses, and to reduce symptoms. Neuromyelitis optica attacks and Neuromyelitis optica relapses are often treated with plasma exchange and corticosteroids. Browse Research Reports: https://www.coherentmarketinsights.com/ongoing- insight/neuromyelitis-optics-therapy-market-4148 © Coherent market Insights. All Rights Reserved

3. REPORT DESCRIPTION Furthermore, rising incidence of neuromyelitis optica disorder among people is expected to propel global neuromyelitis optica therapy market growth. For instance, according to the U.S National Library of Medicine (NHS) 2019 report, prevalence of neuromyelitis optica spectrum disorders (NMOSD) is commonly observed in nations with a predominately non-Caucasian population and estimated to be high as 10 per 100,000 individuals. Global Neuromyelitis Optica Therapy Market Restraints However, high cost of drug such as eculizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD) yet remains one of the major restraints for global neuromyelitis Optica therapy market growth. For instance, cost of eculizumab is US$ 500,000 per patient per year, which is one of the most expensive therapies in the world for the treatment of neuromyelitis optica spectrum disorder (NMOSD). Moreover, side effects associated with the eculizumab such as upper respiratory tract infection, back pain, anemia, nasal congestion, urinary tract infection for the treatment of neuromyelitis optica spectrum disorder (NMOSD) is another factor that is expected to hamper the global neuromyelitis optica therapy market growth. On the other hand, plasma exchange can be used as alternative, if the patient do not respond to intravenous corticosteroids. For long term suppression of disease, immunosuppressive agents such as azathioprine, mycophenolate mofetil, and rituximab are used to prevent the attack. Request a Sample copy of this reports : https://www.coherentmarketinsights.com/insight/request-sample/4148 © Coherent market Insights. All Rights Reserved

4. REPORT DESCRIPTION Asia Pacific is expected to exhibit highest CAGR in the global neuromyelitis optica therapy market in the forecast period due to increasing approval of drug for the treatment of neuromyelitis optica spectrum disorder (NMOSD) by company. For instance, in November 2019, Alexion Pharmaceuticals, Inc. received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its Soliris (eculizumab) drug for the treatment of neuromyelitis optica spectrum disorder (NMOSD) to prevent relapse in patient. Furthermore, increasing number of clinical trials of drug for the treatment of neuromyelitis optica spectrum disorder (NMOSD) by company is another factor that is expected to drive the global neuromyelitis optica therapy market growth. For instance, in September 2019, Chugai Pharmaceutical Co., Ltd. announced positive results of its phase 3 clinical study of satralizumab drug, for the treatment of neuromyelitis optica spectrum disorder (NMOSD). From the same source, in 2019, Satralizumab had shown safety profile during the clinical trial and is first investigational drug that had demonstrated benefits both as a monotherapy and add-on therapy to baseline treatment in two different clinical trials. Furthermore, from the same source, in 2019, Chugai Pharmaceutical Co., Ltd also announced that they are going to collaborate with F. Hoffmann-La Roche AG Company. The main objective of this collaboration with Hoffmann-La Roche AG company is to file global regulatory application and bring Satralizumab as a potential new treatment to patients as soon as possible. Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/4148 © Coherent market Insights. All Rights Reserved

5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved